Clinical trial
Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment…
NCT00276341 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00276341 |
|---|---|
| Title | Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis |
| Official title | Efficacy of EGb 761® 120mg Twice a Day Versus Placebo on Cognitive Impairment in Patients With Multiple Sclerosis. A Randomised, Double-blind, Multicentre, Parallel Groups Placebo Controlled Phase III Study. |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Relapsing-Remitting |
| Intervention type | Drug |
| Interventions | EGb 761® (Tanakan®) |
| Enrollment | 47 |
| Start date | Aug 26, 2003 |
| Completion | Dec 8, 2005 |
| First posted | Jan 13, 2006 |
| Last update posted | Mar 7, 2024 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: